for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

La Jolla Pharmaceutical Company

LJPC.OQ

Latest Trade

7.08USD

Change

0.02(+0.28%)

Volume

79,314

Today's Range

7.01

 - 

7.29

52 Week Range

2.31

 - 

13.88

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.06
Open
7.01
Volume
79,314
3M AVG Volume
26.70
Today's High
7.29
Today's Low
7.01
52 Week High
13.88
52 Week Low
2.31
Shares Out (MIL)
27.15
Market Cap (MIL)
196.08
Forward P/E
--
Dividend (Yield %)
--

Next Event

La Jolla Pharmaceutical Co at Cowen HealthCare Conference

Latest Developments

More

La Jolla Pharmaceutical Says Preliminary GIAPREZA Net Sales Were $7.2 Mln For 3 Months Ended Dec 31

La Jolla Pharmaceutical Says Board Approved Restructuring Plan That Reduced Headcount

La Jolla Pharmaceutical To Discontinue Study Due To Lack Of Efficacy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Contact Info

4550 Towne Centre Ct

+1.858.2074264

http://www.ljpc.com

Executive Leadership

Kevin C. Tang

Chairman of the Board

Dennis M. Mulroy

Chief Financial Officer

James M. Rolke

Chief Scientific Officer

Lakhmir S. Chawla

Chief Medical Officer

Darryl Wellinghoff

Chief Commercial Officer

Key Stats

2.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-4.540

2017

-5.410

2018

-7.850

2019(E)

-4.315
Price To Earnings (TTM)
--
Price To Sales (TTM)
9.81
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-80.45
Return on Equity (TTM)
-70.79

Latest News

Latest News

BRIEF-La Jolla PharmaAnnounces Launch Of Giapreza In United States

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES LAUNCH OF GIAPREZA™ (ANGIOTENSIN II) IN THE UNITED STATES

BRIEF-La Jolla Pharmaceutical Announces Pricing Of Public Offering Of Common Stock

* SAYS PUBLIC OFFERING OF 3.40 MILLION COMMON SHARES PRICED AT $29.50PER SHARE

BRIEF-La Jolla Pharmaceutical Company Announces $100 Million Public Offering Of Common Stock

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES $100 MILLION PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-La Jolla Pharmaceutical Q4 Loss Per Share $1.74

* MPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS

BRIEF-La Jolla Pharmaceutical Announces Treatment Of First Patient In Giapreza Pediatric Study

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES THE TREATMENT OF FIRST PATIENT IN GIAPREZA (ANGIOTENSIN II) PEDIATRIC STUDY Source text for Eikon: Further company coverage:

BRIEF-La Jolla Pharmaceutical Says Established Wholesale Acquisition Cost of Single-Dose Vial Of Giapreza At $1,500/ Vial

* LA JOLLA PHARMACEUTICAL CO - ESTABLISHED WHOLESALE ACQUISITION COST OF $1,500 PER VIAL FOR A 1 ML, SINGLE-DOSE, 2.5 MG/ML VIAL OF GIAPREZA Source text: (http://bit.ly/2nm3hfv) Further company coverage:

BRIEF-Broadfin Capital Reports 5 Percent Passive Stake In La Jolla Pharmaceutical - SEC Filing

* BROADFIN CAPITAL LLC REPORTS 5 PERCENT PASSIVE STAKE IN LA JOLLA PHARMACEUTICAL CO AS OF JAN 9 - SEC FILING Source text: (http://bit.ly/2D4NbRm) Further company coverage:

BRIEF-La Jolla Pharmaceutical Says Cash Resources Are Expected To Fund Co Into Second Half Of 2018

* LA JOLLA PHARMACEUTICAL SAYS CASH RESOURCES ARE EXPECTED TO FUND CO INTO SECOND HALF OF 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2BTfmOK) Further company coverage:

FDA approves La Jolla's low blood pressure drug

La Jolla Pharmaceutical said on Thursday the U.S. Food and Drug Administration had approved its drug, Giapreza, to treat dangerously low blood pressure.

BRIEF-La Jolla Says FDA Approved Drug To Treat Critically Low Blood Pressure

* U.S. FOOD AND DRUG ADMINISTRATION SAYS APPROVED GIAPREZA (ANGIOTENSIN II) TO TREAT DANGEROUSLY LOW BLOOD PRESSURE

BRIEF-La Jolla Pharmaceutical Initiates Multicenter, Randomized, Phase 2 Clinical Study Of LJPC‑401

* INITIATION OF MULTICENTER, RANDOMIZED, PHASE 2 CLINICAL STUDY OF LJPC-401 IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS Source text for Eikon: Further company coverage:

BRIEF-La Jolla Pharma files for mixed shelf of up to $150 mln

* Files for mixed shelf of up to $150 million - SEC filing Source text : [http://bit.ly/2zK9cPg] Further company coverage:

BRIEF-La Jolla reports Q3 loss $1.19/shr

* La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2017 and recent corporate progress

BRIEF-Prudential Financial reports 10.1 pct passive stake ​in La Jolla Pharmaceutical

* Prudential Financial Inc reports 10.1 percent passive stake in La Jolla Pharmaceutical Co as of Sept 30 - sec filing Source text : [http://bit.ly/2g07Ckv] Further company coverage:

BRIEF-La Jolla Pharmaceutical Co announces intent to submit Marketing Authorization Application for LJPC-501

* La Jolla Pharmaceutical Company announces intent to submit Marketing Authorization Application for LJPC-501 in the third quarter of 2018 Source text for Eikon: Further company coverage:

BRIEF-FDA accepts La Jolla Pharmaceutical's NDA for LJPC-501

* La Jolla Pharmaceutical Company announces U.S. Fda acceptance of new drug application for LJPC-501

BRIEF-La Jolla Pharma ‍announces launch of expanded access program for LJPC-501​

* La Jolla Pharmaceutical Co - announces launch of expanded access program for LJPC-501 Source text for Eikon: Further company coverage:

BRIEF-La Jolla Pharmaceutical reports CEO compensation

* CEO George Tidmarsh's 2016 total compensation was $4.7 million versus $15.6 million in 2015 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-La Jolla quarterly loss per share $1.21

* La Jolla Pharmaceutical Company announces financial results for the three and six months ended June 30, 2017 and recent corporate progress

BRIEF-La Jolla Pharmaceutical quarterly loss per share $1.26

* La Jolla Pharmaceutical Company announces financial results for the three months ended march 31, 2017 and recent corporate progress

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up